Abstract
Alzheimer's disease (AD) is associated with deposition of amyloid-β (Aβ) in the brain, which is reflected by low concentration of the Aβ(1-42) peptide in the cerebrospinal fluid (CSF). The γ-secretase inhibitor LY450139 (semagacestat) lowers plasma Aβ(1-40) and Aβ(1-42) in a dose-dependent manner but has no clear effect on the CSF level of these isoforms. Less is known about the potent γ-secretase modulator E2012. Using targeted proteomics techniques, we recently identified several shorter Aβ isoforms in CSF, such as Aβ(1-16), which is produced by a novel pathway. In a Phase II clinical trial on AD patients, Aβ(1-14), Aβ(1-15) and Aβ(1-16) increased several-fold during γ-secretase inhibitor treatment. In the present study, 9 dogs were treated with a single dose of the γ-secretase modulator E2012, the γ-secretase inhibitor LY450139, or vehicle with a dosing interval of 1 week. The CSF Aβ isoform pattern was analyzed by immunoprecipitation combined with MALDI-TOF mass spectrometry. We show here that Aβ(1-15) and Aβ(1-16) increase while Aβ(1-34) decreases in response to treatment with the γ-secretase inhibitor LY450139, which is in agreement with previous studies. The isoform Aβ(1-37) was significantly increased in a dose-dependen...Continue Reading
Citations
Sep 8, 2011·The Journal of Biological Chemistry·Amelie EbkeHarald Steiner
Feb 16, 2012·The Journal of Biological Chemistry·Tomas BorgegardJohan Lundkvist
Aug 2, 2012·The Journal of Biological Chemistry·Johanna WanngrenHelena Karlström
Feb 14, 2012·PloS One·Niklas MattssonErik Portelius
Feb 7, 2012·Molecular Medicine Reports·Erik PorteliusRaquel Sanchez-Valle
Feb 12, 2013·The Journal of Biological Chemistry·Nikolay PozdnyakovDouglas S Johnson
Apr 26, 2013·Biochemistry·Christina J CrumpYue-Ming Li
Dec 23, 2015·Alzheimer's Research & Therapy·Simon SjödinErik Portelius
Jan 8, 2015·Frontiers in Cellular Neuroscience·Xian ZhangYun-Wu Zhang
Dec 31, 2016·Journal of Alzheimer's Disease : JAD·Herman BorghysJoseph A Araujo
Mar 23, 2017·Cold Spring Harbor Perspectives in Medicine·Douglas S JohnsonPeter H St George-Hyslop
Mar 2, 2011·The Journal of Biological Chemistry·Benedikt KretnerHarald Steiner
Jun 30, 2012·Expert Opinion on Investigational Drugs·Petra DunkelPéter Mátyus
Nov 19, 2014·Alzheimer's Research & Therapy·Erik PorteliusKaj Blennow
Jan 5, 2013·European Journal of Clinical Pharmacology·Camilla NivaSandra A G Visser
Feb 4, 2012·Neuro-degenerative Diseases·Erik PorteliusKaj Blennow
Sep 1, 2012·Metabolic Brain Disease·Niklas MattssonErik Portelius
Dec 12, 2012·Neuromolecular Medicine·Magdalena NutuKaj Blennow
Dec 18, 2013·Journal of Clinical Pharmacology·Yanke YuJim Ferry
Jul 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Simone ListaHarald Hampel
Nov 26, 2010·Journal of Neurochemistry·Stefanie HahnSascha Weggen
Jan 15, 2011·Expert Opinion on Therapeutic Patents·Martin PetterssonDouglas S Johnson
Dec 20, 2013·The Journal of Biological Chemistry·Yong RanTodd E Golde
Jul 24, 2013·Expert Opinion on Therapeutic Patents·Martin PetterssonDouglas S Johnson
Oct 3, 2020·Bioorganic & Medicinal Chemistry·Kevin D RynearsonSteven L Wagner
Apr 7, 2020·Seminars in Cell & Developmental Biology·Pengju NieYue-Ming Li
Jan 17, 2014·Journal of Medicinal Chemistry·Martin PetterssonChristopher J O'Donnell